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Abstract. Host immunity plays an important role in response to antimalarial therapy but is poorly understood. To
test whether T cell activation is a risk factor for antimalarial treatment failure, we studied CD4+ and CD8+ T cell
activation in 31 human immunodeficiency virus–negative Ugandan patients 5–37 years of age who were treated for
uncomplicated Plasmodium falciparum malaria. Increased CD4+ T cell activation, as indicated by co-expression of
HLA-DR and CD38, was an independent risk factor for treatment failure (hazard ratio  2.45, 95% confidence inter-
val 1.02–5.89, P 0.05) in multivariate analysis controlling for age, baseline temperature, and pre-treatment parasite
density. The results provide insight into the role of cellular immunity in response to antimalarial therapy and underscore
the need to investigate the mechanisms behind immune activation.
Plasmodium falciparum malaria is a major source of mor-
bidity and mortality, especially in sub-Saharan Africa. The
complexity of the parasite life cycle and high diversity of
strains has limited progress in understanding the immuno-
pathogenesis of this disease. The presence of P. falciparum-
specific antibodies have previously been associated with im-
proved responses to antimalarial treatment.1–3 The role of T
cell responses in malaria has been less well defined, although
specific cytokine profiles have been associated with protec-
tion against severe disease.4–7 Expression of CD38 and HLA-
DR on CD4+ and CD8+ T cells is thought to provide a general
assessment of the extent to which a pathogen activates the
immune system, but this expression does not necessarily cor-
relate with the effectiveness of the T cell response in elimi-
nating the pathogen. These activation parameters have been
studied most comprehensively in human immunodeficiency
virus (HIV) infection, where they have been shown to be very
strong independent predictors of disease progression and
death.8,9 Increased expression of these markers has also been
associated with Mycobacterium tuberculosis and Epstein-Barr
virus infections;10,11 however, its prognostic value has not
been reported. In these diseases, the mechanism of immune
activation is unclear and may represent both specific and non-
specific bystander activation.12,13
Few studies of immune activation in malaria have been
reported, and to our knowledge, none have investigated this
parameter in relation to treatment outcome. Available stud-
ies agree that malaria is associated with increased activation
of the immune system.14,15 Independent predictors of treat-
ment failure in uncomplicated P. falciparum malaria con-
firmed in multiple studies include young age, high tempera-
ture at presentation, and high pre-treatment parasite den-
sity.16 We hypothesized that high temperature might be a
surrogate marker for immune activation and investigated
whether this parameter is associated with treatment outcome.
Our investigation was part of a larger study conducted be-
tween December 2003 and August 2004 at Mulago Hospital in
Kampala, Uganda to assess the dynamics of parasite clear-
ance after standard antimalarial therapy. Patients were en-
rolled in the main study if they were  6 months of age, had
uncomplicated P. falciparum malaria with a parasite density
less than 400,000/L, and no evidence of any concomitant
febrile illness. Convenience sampling was used to identify a
subgroup of patients  5 years of age (to ensure adequate
blood volumes) for participation in the immunology studies.
After the clinical study, patient identifiers were delinked and
HIV testing was conducted with two parallel enzyme-linked
immunosorbent assays followed by Western blots for discor-
dant results. Patients infected with HIV were excluded from
the immunologic studies.
All patients were given directly observed therapy with chlo-
roquine (25 mg/kg over a three-day period) plus sulfadoxine-
pyrimethamine (25 mg/kg of sulfadoxine and 1.25 mg/kg of
pyrimethamine given as a single dose), the recommended
first-line therapy for uncomplicated malaria in Uganda at the
time of the study. Patients were followed for 42 days and
treatment outcomes classified according to the World Health
Organization classification system as early treatment failure
(ETF), late clinical failure (LCF), late parasitologic failure
(LPF), or adequate clinical and parasitologic response
(ACPR).17 For all patients requiring repeat therapy (ETF,
LCF, and LPF), molecular genotyping was conducted to dis-
tinguish recrudescence (true treatment failure) from new in-
fection, as previously described.18 Treatment failure was de-
fined as all ETFs and any LTF or LPF due to recrudescence.
The study was reviewed and approved by the Institutional
Review Boards of the University of California, San Francisco
and Makerere University (Kampala, Uganda). All study par-
ticipants provided written informed consent.
Immediately before the initiation of therapy, blood was
drawn and peripheral blood mononuclear cells (PBMCs)
were isolated by Ficoll-Hypaque gradient centrifugation.
Freshly isolated PBMCs were analyzed for CD4+ and CD8+ T
cell activation using the FACScalibur system (Becton Dick-
inson, Franklin Lakes, NJ) as previously described.19 Asso-
ciations between independent variables and levels of immune
activation were made using multivariate linear regression.
The risk of treatment failure was estimated using the Kaplan-
Meier product limit formula with censoring for new infec-
tions. Associations between exposure variables and treatment
failure were estimated using the Cox proportional hazard
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model. All P values were two-sided, and a value  0.05 was
considered statistically significant.
A total of 230 patients completed the main study, of which
146 were  5 years of age. Immunologic studies were per-
formed on 33 patients. Two patients were excluded because
of HIV infection, giving a total sample size of 31. The average
age of participants in the immunology study was 12.6 years
(range 5–37), and 52% were female. The average tympanic
temperature at presentation was 37.6°C (range  35.3–
40.9°C). The geometric mean parasite density was 27,897
asexual parasite/L (range 1,560–229,120). Compared with
patients  5 years of age not included in the immunologic
sub-study, patients included in the immunologic sub-study did
not differ with respect to age, temperature, or parasite density
(P > 0.05 for all comparisons). Fifty-five percent of the pa-
tients required repeat therapy after 42 days; however, after
adjustment by genotyping to exclude new infections, the risk
of treatment failure was 29%.
To investigate whether immune activation is associated
with clinical predictors of treatment failure, we performed
multivariate linear regression (Table 1). Activated T cells
were defined as the percentage of CD4+ or CD8+ T cells that
co-express CD38 and HLA-DR. Because CD38 is known to
be an early T cell differentiation marker, an inverse associa-
tion with age was anticipated and controlled for in all analy-
ses. Interestingly, CD4+ activation, but not CD8+ T cell acti-
vation, was strongly associated with temperature at presenta-
tion (P 0.005 and P 0.86, respectively). This association
was independent of age and parasite density.
We next investigated whether T cell activation was a pre-
dictor for treatment failure in a multivariate model control-
ling for age, temperature, and parasite density. Decreasing
age and increasing baseline temperature were associated with
an increased risk of treatment failure, as expected, although
these associations did not reach statistical significance (base-
line model) (Table 2). The association of age and temperature
with treatment outcome reached statistical significance in the
larger cohort of patients  5 years and older (n 146) from
which the immunologic sub-study was sampled (hazard ratio
[HR]  0.58, P  0.001 and HR  1.46, P  0.004, respec-
tively) suggesting that the lack of significance in the immu-
nology study was due to small sample size. When immune
activation was added to the model including age, tempera-
ture, and parasite density, a significant association was ob-
served between CD4+ T cell activation and treatment failure
(HR  2.45, P  0.05). Moreover, addition of CD4+ T cell
activation to the multivariate models caused the trend to-
wards association between high temperature and treatment
failure to disappear (HR  0.98, P  0.95). Finally, the as-
sociations between CD4+ T cell activation and treatment fail-
ure were consistent when temperature was removed from the
models (HR  2.41, P  0.02). The CD8+ T cell activation
was not significantly associated with treatment outcome.
Clinical response to antimalarial therapy involves a com-
plex interaction between parasites, drugs, and host response.
Although the immune system is believed to play a critical role
in the successful treatment of malaria, few immune correlates
have been shown to be predictors of treatment success or
failure. We found that CD4+ T cell activation was strongly
associated with temperature at presentation. Furthermore, in
multivariate analyses, CD4+ T cell activation, but not tem-
perature, was an independent predictor of treatment failure
after antimalarial therapy. These findings suggest that previ-
ous associations between higher baseline temperature and
treatment failure may have been confounded by CD4+ T cell
activation. Our findings suggest that CD4+ T cell activation
rather than fever plays a causal role in response to antima-
larial therapy.
Why should increased CD4+ T cell activation, presumably a
sign of a robust immune response, be a risk factor for treat-
ment failure? One hypothesis is that our immunophenotype
for immune activation represents a dysfunctional immune re-
sponse. Alternatively, a highly stimulated immune system
might result from infection with a parasite strain against
which the host has limited prior immunity. Pre-existing anti-
bodies might improve treatment outcome1–3 and limit the de-
gree of T cell activation, such that only novel strains, which
are most likely to evade immune responses and contribute to
drug failure, elicit heightened T cell activation. Previous stud-
ies have suggested a direct immune correlate between T cell-
mediated interferon- and tumor necrosis factor- produc-
tion and natural immunity against P. falciparum.4–7 It is also
interesting to speculate why we did not observe correlation of
treatment failure with CD8+ T cell activation in our study,
which may imply a larger role for CD4+ cells rather than
CD8+ T cells in immune responses to malaria.
The primary limitation of our study is small sample size for
our immunology sub-study because of cost and logistic con-
straints of performing the assays on site in Uganda. The lack
of statistically significant associations between treatment out-
TABLE 1
Associations between clinical factors and immune activation
Dependent variable*
Independent
variable†
Multivariate
coefficient‡ (P)
CD4+ T cell activation Temperature§ 2.00 (0.005)
Parasite density¶ −1.26 (0.13)
CD8+ T cell activation Temperature −0.30 (0.86)
Parasite density −1.14 (0.60)
* Percentage of CD4 or CD8 cells co-expressing CD38 and HLA-DR.
† All analyses are controlled for age.
‡ Coefficient represents the percent increase in immune activation per unit increase in
independent variable. Bold values are statisticaly significant with P  0.05.
§ Per 1°C increase.
¶ Per increase in natural log.
TABLE 2
Associations between immune activation and antimalarial treat-
ment failure
Model Covariates HR (95% CI)* P
Baseline Age† 0.66 (0.38–1.12) 0.12
Temperature‡ 1.37 (0.78–2.40) 0.28
Parasite density§ 0.75 (0.39–1.42) 0.37
CD4+HLA-DR+CD38+ Age† 0.62 (0.32–1.23) 0.17
Temperature‡ 0.98 (0.50–1.92) 0.95
Parasite density§ 0.91 (0.43–1.93) 0.81
Immune activation¶ 2.45 (1.02–5.89) 0.05
CD8+HLA-DR+CD38+ Age† 0.56 (0.31–1.04) 0.07
Temperature‡ 1.49 (0.84–2.64) 0.17
Parasite density§ 0.61 (0.28–1.33) 0.22
Immune activation¶ 1.17 (0.85–1.59) 0.33
* HR  hazard ratio using Cox proportional hazards model. CI  confidence interval.
Bold values are statistically significant with P  0.05.
† Per five year increase.
‡ Per 1°C increase.
§ Per increase in natural log.
¶ Per 5% increase.
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come and age or temperature is likely the result of the small
sample size because associations between outcome and these
parameters have been independently confirmed in six previ-
ous studies in Kampala16 and in the larger cohort from which
the immunologic sub-study was sampled. The fact that we
were able to observe a significant association between T cell
activation and response to antimalarial therapy with such a
limited sample size reflects the strength of this association.
Immune activation is predictive of HIV disease progression
in antiretroviral-naive populations and has been associated
with lower CD4+ T cell increases after initiation of antiretro-
viral treatment.8,9,20,21 To our knowledge, this is the first as-
sessment of immune activation as a predictor for treatment
failure in malaria. Our findings underscore the need to inves-
tigate the mechanisms behind immune activation. The devel-
opment of a malaria vaccine will be facilitated by understand-
ing this and other immune correlates of protection and treat-
ment outcome. Additional studies of relationships between
immune activation and treatment outcomes, including longi-
tudinal studies, are needed to better delineate the importance
of these parameters.
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